Top 5 Wine And Spirits VC (Venture Capital) Funds in Germany in May 2025

Last updated: May 2025 A list of 5 VC (Venture Capital) funds that invest in Wine and spirits startups based in Germany. We rank investors based on the number of investments they made in Wine and spirits companies from Germany. We update this investor list every month.

Top 5 Wine And Spirits VC (Venture Capital) Funds in Germany in May 2025

Investor	Wine And Spirits Germany investments
Loyal VC	2
Brandenburg Kapital	1
Ace Ventures	1
CNB Capital	1
SquareOne	1

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

Loyal runs a global venture fund with quarterly redemptions and a proprietary gate-stage process, reducing investment bias and unlocking greater returns. Partnered with INSEAD, Founder Institute, and 500+ advisors, we are Loyal to the world with 250+ investments in 50+ countries.

Investment focus

Artificial Intelligence, Software, E-Commerce
Pre-Seed, Seed, Funding Round
United States, Canada, United Kingdom

Portfolio highlights

Edept — enabling global career mobility, transforming student success stories
Aisel Health — Aisel Health provides AI that imitates psychiatrists for psychiatric clinics and hospitals to ensure efficient patient access to care.
The Leaf Protein Company — Unlocking Earth's most abundant source of proteins - green leaves.

With a track record of over 20 years in venture capital and experience from more than 200 investments in numerous companies BFB Brandenburg Kapital GmbH (BFB) is the most active equity investor in Brandenburg. BFB invests in fast-growing technology-orientated companies throughout the whole life-cycle. Target sectors are ICT/Digital Economy,Life Science, MedTech, Proptech, Industrial Applications. BFB invests in companies based in or with facilities in Brandenburg. The current VC fund is financed by the European Regional Development Fund (ERDF) an Investitionsbank des Landes Brandenburg (ILB).

Investment focus

Information Technology, Software, Health Care
Seed, Series A, Funding Round
Germany, United Kingdom

Portfolio highlights

family.cards — Family.cards provides elders with barrier-free access to digital solutions and all the tools they need to manage their circumstances.
Green Fusion — Green Fusion is developing a cloud-based energy manager for the intelligent control of heat, electricity, and e-mobility. The focus here is on hybrid heating systems in buildings such as heat pumps + gas boilers and the coupling to photovoltaic systems and electric vehicle charging stations.
Sphingotec GmbH — Improving patient outcomes with innovative diagnostics for critical care: Actionable insights in real-time

Ace Ventures was designed to help new ideas, smart people and great companies to successfully enter the Internet business in Germany.

Investment focus

Apps, Electronics, Wine And Spirits
Series B, Seed, Series A
Germany, United States, Italy

Portfolio highlights

iMediSync — iMediSync provides automatic brain wave analysis and neuromodulation solutions.
Joy — Experience wedding planning the way it should be, from beautiful wedding websites and invitations, to registries and online RSVP.
Kither Biotech — Kither Biotech is a pharmaceutical product company that focuses its R&D activities on the development of new drugs. The R&D activities of the company mainly involve the development of new drugs to treat chronic inflammatory diseases.In recent years Kither has focused its first line of activities on the development of a small peptide(KIT2014) developed internally for the treatment of cystic fibrosis, a disease that predominantly affects the lungs and that currently has no cure. The KIT2014 peptide was assigned the Orphan Drug designation from the European Medicines Agency. The KIT2014 compound is currently undergoing the pre-clinical phase of clinical development.Kither’s product portfolio also includes a molecule (CL27), also developed internally, that is being developed for the treatment of Chronic Obstructive Pulmonary Diseases and Allergic Asthma. The company is about to start the pre-clinical phase of development of the CL27 molecule.

CNB Capital believes in the power of technology-driven entrepreneurship. We understand real innovation creates moat and defensibility. We provide long-term commitment, building an enduring partnership without the usual exit pressure.